Attached files
| file | filename |
|---|---|
| EX-23.5 - EX-23.5 - NantHealth, Inc. | d46244dex235.htm |
| EX-23.3 - EX-23.3 - NantHealth, Inc. | d46244dex233.htm |
| EX-23.1 - EX-23.1 - NantHealth, Inc. | d46244dex231.htm |
| EX-21.1 - EX-21.1 - NantHealth, Inc. | d46244dex211.htm |
| EX-4.1 - EX-4.1 - NantHealth, Inc. | d46244dex41.htm |
| S-1/A - S-1/A#2 - NantHealth, Inc. | d46244ds1a.htm |
Exhibit 23.4
CONSENT OF INDEPENDENT PUBLIC ACCOUNTING FIRM
Nant Health, LLC
Culver City, California
We hereby consent to use in the Prospectus constituting a part of this Registration Statement of our report dated July 24, 2015, relating to the consolidated financial statements of Expression Pathology Incorporated (d/b/a OncoPlex Diagnostics), which is referred to in that Prospectus. Our report contains an explanatory paragraph regarding the ability of Expression Pathology Incorporated (d/b/a OncoPlex Diagnostics) to continue as a going concern.
We also consent to the reference to us under the caption “Experts” in the Prospectus.
/s/ BDO USA, LLP
McLean, Virginia
May 19, 2016